

## **Correlagen Diagnostics and Protedyne Corporation Partner to Form Correlagen GeneXchange™**

April 7, 2006 – Cambridge, MA – Correlagen Diagnostics, a molecular diagnostics clinical reference laboratory, and Protedyne Corporation, an advanced industrial laboratory automation provider, today announced the creation of Correlagen GeneXchange.

GeneXchange combines Correlagen genetic sequence testing methods and software with Protedyne's novel Radius™ robotic system. GeneXchange enables leading academic medical centers to bring genetic sequencing for patient care into their diagnostic laboratories. The GeneXchange services include assay development protocols, software to support ordering gene test reagents and supplies, a next-generation robotics platform (Radius), and a data analytics service to optimize the value and validity of results reporting. Correlagen GeneXchange will distribute the GeneXchange services to academic medical centers. This integrated end-to-end automated solution for genetic testing within the healthcare institution will lower the cost of testing, improve turn around time, and deliver consistent results. Correlagen and Protedyne will maintain their focus on their core businesses and continue to operate independently.

“Correlagen has had remarkable success automating complex testing protocols on their Protedyne BioCube System,” said Fran Tuttle, President and CEO of Protedyne. “It is quite a resounding endorsement that they have elected to take the next step with us to form GeneXchange to distribute this capability to the academic medical center market. By combining the expertise of the two companies, we will be able to provide healthcare organizations with an advanced product to quickly and cost-effectively manage genetic testing.”

“Academic medical centers have told us of their need for a diagnostic sequencing platform to enable them to fully appreciate the benefits of clinical insights derived from genetic testing,” said Dr. David Margulies, President and CEO of Correlagen Diagnostics. “The combination of Correlagen's application software and sequencing protocols (together, our 'Bioware') and Protedyne's remarkable instrument create a unique capability for the sophisticated medical center. Correlagen GeneXchange will dramatically reduce the cost and complexity of diagnostic sequencing for the laboratory. We expect the first system to be in production by the third quarter of 2006.”

### **About Correlagen**

*Correlagen Diagnostics, Inc. develops and commercializes genetic testing services using a high throughput automated approach that incorporates sequencing, variant analysis and results reporting. By focusing on Genes That Matter™ -- where variation is correlated with disease and where testing would impact diagnosis and treatment--, Correlagen is accelerating and increasing the use of genetic*

testing in clinical practice. Correlagen Diagnostics is based in Cambridge, Massachusetts.

[www.correlagen.com](http://www.correlagen.com)

### **About Protedyne**

*Protedyne was a pioneer and is now the acknowledged leader in bringing the industrial design for automation philosophy to genome-based drug research. Our mission is to design, build, market and service world-class robotic solutions that dramatically improve performance in academic, drug discovery and commercial reference laboratories. Protedyne is headquartered in Windsor, Connecticut, USA. For more information call +1 (860) 683-1860 or visit Protedyne on the web at [www.protedyne.com](http://www.protedyne.com).*

# # #

Contact: Joyce S. Samet, Correlagen Diagnostics  
Senior Vice President  
617.577.0152  
[jsamet@correlagen.com](mailto:jsamet@correlagen.com)